An efficacy trial of the malaria vaccine SPf66 in Gambian infants - Second year of follow-up

Vaccine

Volumn 16, Issue 1, 1998, Pages 62-67

  Bojang, K A ^a   Obaro, S K ^a   D'Alessandro, U ^a,b   Bennett, S ^c   Langerock, P ^a   Targett, G A T ^c   Greenwood, B M ^c  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Malaria; Malaria vaccine; Plasmodium falciparum; Spf66

Indexed keywords

MALARIA VACCINE; POLYPEPTIDE;

ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; GAMBIA; HUMAN; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALARIA; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; VACCINATION;

ANIMALS; FEMALE; FOLLOW-UP STUDIES; GAMBIA; HUMANS; INFANT; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS; VACCINES, SYNTHETIC;

EID: 0031986509     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00159-X     Document Type: Article

References (15)

1. Patarroyo M.E., Amador R., Clavijo P.et al. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum. Nature. 332:1988;158-161.
2. Valero M.V., Amador L.R., Galindo C.et al. Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia. Lancet. 341:1993;705-710.
3. Noya O., Berti Y.G., de Noya B.A.et al. A population-based clinical trial with SPf66 synthetic Plasmodium falciparum malaria vaccine in Venezuela. J. Infect. Dis. 170:1994;396-402.
4. Sempertegui F., Estrella B., Moscoso J.et al. Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in a randomized double-blind placebo-controlled field trial in an area of Ecuador. Vaccine. 12:1994;337-342.
5. Alonso P.L., Smith T., Armstrong-Schellenberg J.R.M.et al. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in Southern Tanzania. Lancet. 344:1994;1175-1181.
6. Leach A., Drakeley C.J., D'Alessandro U.et al. A pilot safety and immunogenicity study of the malaria vaccine SPf66 in Gambian infants. Parasite Immunol. 17:1995;441-444.
7. D'Alessandro U., Leach A., Drakeley C.J.et al. Efficacy trial of malaria vaccine SPf66 in Gambian infants. Lancet. 346:1995;462-467.
8. Nosten F., Luxemburger C., Kyle D.E.et al. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwest Thailand. Lancet. 348:1996;701-707.
9. Greenwood B.M., Armstrong J.R.M. Comparison of two simple methods for determining malaria parasite density. Trans. Roy. Soc. Trop. Med. Hyg. 85:1991;186-188.
10. Smith T., Armstrong-Schellenberg J.R.M., Hayes R. Attributable fraction estimates and case definition for malaria in endemic areas. Stat. Med. 13:1994;2345-2358.
11. Alonso P.L., Smith T.A., Armstrong-Schellenberg J.R.M.et al. Duration of protection and age-dependence of the effects of the SPf66 malaria vaccine in African children exposed to intense transmission of Plasmodium falciparum. J. Infect. Dis. 174:1996;367-372.
12. Patarroyo M.E., Vinasco J., Amador R.et al. Genetic control of the immune response to a synthetic vaccine against Plasmodium falciparum. Parasite Immunol. 13:1991;509-516.
13. Murillo L.S., Tenjo F., Clavijo O.et al. A specific T-cell receptor genotype preference in the immune response to the synthetic P. falciparum malaria vaccine. Parasite Immunol. 14:1992;87-94.
14. Beck H.-P., Felger I., Baker M.et al. Evidence of HLA Class II association with antibody response against the malaria vaccine SPf66 in a naturally exposed population. Am. J. Trop. Med. Hyg. 53:1995;284-288.
15. Cooper J.A. Merozoite surface antigen-1 of Plasmodium falciparum. Parasitol. Today. 9:1993;50-54.